Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment

NCT07051486 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT07051486
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07051486 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
October 11, 2025
Completion date
August 31, 2026
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic cervical cancer